Alkem Laboratories Ltd Stock Price Today (NSE: ALKEM)
Fundamental Score
Alkem Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Alkem Laboratories Ltd share price today is ₹5659.00, up +1.03% on NSE/BSE as of 20 July 2026. Alkem Laboratories Ltd (ALKEM) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹67.70K (Cr). The 52-week high for ALKEM share price is ₹5933.50 and the 52-week low is ₹4738.50. At a P/E ratio of 27.79x, ALKEM is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 18.88% and a debt-to-equity ratio of 0.15.
Alkem Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Alkem Laboratories Ltd share price chart: 6.09% return over the past month. 52-week high ₹5933.50, 52-week low ₹4738.50.
Alkem Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹5595.00 | ₹5689.00 | ₹5564.00 | ₹5653.50 | 1.09L (Cr) | |
| ₹5709.00 | ₹5709.00 | ₹5539.00 | ₹5563.00 | 70.60K (Cr) | |
| ₹5659.50 | ₹5735.50 | ₹5642.50 | ₹5709.00 | 67.61K (Cr) | |
| ₹5645.00 | ₹5706.50 | ₹5574.00 | ₹5659.00 | 2.13L (Cr) | |
| ₹5546.50 | ₹5665.00 | ₹5515.50 | ₹5601.50 | 5.21L (Cr) | |
| ₹5615.50 | ₹5684.00 | ₹5548.50 | ₹5567.00 | 2.19L (Cr) | |
| ₹5699.00 | ₹5727.50 | ₹5635.00 | ₹5669.50 | 1.04L (Cr) | |
| ₹5634.00 | ₹5695.00 | ₹5602.50 | ₹5648.50 | 39.73K (Cr) | |
| ₹5679.50 | ₹5729.50 | ₹5562.50 | ₹5606.00 | 1.01L (Cr) | |
| ₹5635.00 | ₹5735.00 | ₹5608.00 | ₹5667.50 | 2.00L (Cr) |
Alkem Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹5594.00 | ₹5735.50 | ₹5487.00 | ₹5653.50 | +1.06% | |
| ₹5443.50 | ₹5608.00 | ₹5162.50 | ₹5570.00 | +2.32% | |
| ₹5382.00 | ₹5789.00 | ₹5313.00 | ₹5498.00 | +2.16% | |
| ₹5320.50 | ₹5735.00 | ₹5075.00 | ₹5400.00 | +1.49% | |
| ₹5415.00 | ₹5665.00 | ₹5111.50 | ₹5299.00 | -2.14% | |
| ₹5616.00 | ₹5915.00 | ₹5307.71 | ₹5639.50 | +0.42% | |
| ₹5477.00 | ₹5933.50 | ₹5384.00 | ₹5677.50 | +3.66% | |
| ₹5712.00 | ₹5736.00 | ₹5405.00 | ₹5506.50 | -3.60% | |
| ₹5519.50 | ₹5868.00 | ₹5499.00 | ₹5685.00 | +3.00% | |
| ₹5392.00 | ₹5648.00 | ₹5321.00 | ₹5506.50 | +2.12% | |
| ₹5310.00 | ₹5591.00 | ₹5204.50 | ₹5425.00 | +2.17% | |
| ₹5032.00 | ₹5479.00 | ₹4738.50 | ₹5303.50 | +5.40% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Alkem's transition to higher-value segments hinges on Occlutech's success, masking near-term profit concerns.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Alkem is expanding its manufacturing footprint and product portfolio. They've increased investment in their Ujjain facility. Alkem launched A to Z Daily, a multivitamin supplement. They also launched Semaglutide injection in India, starting at per week.
CORE STORY (THE REAL GAME)
Alkem is no longer just a generics player. They're strategically moving into higher-value segments like medical devices and complex generics to secure future growth and global market access.
- Occlutech acquisition provides entry into the high-growth cardiovascular device market
- Q3FY26 revenue growth of 10.7% demonstrates continued market traction
- Semaglutide launch targets a significant market opportunity in India
- Successful integration of Occlutech and realization of synergies
- Faster-than-expected growth in the Indian Semaglutide market
- New product launches in the US market
- Occlutech's history of losses raises integration risks
- Increased investment in Ujjain facility may pressure near-term margins
- Promoter stake decreased by 1.84%
FII increased stake by 0.36%, DII increased stake by 0.13%, while Promoter decreased stake by 1.84%
Indian pharma sector benefits from policy support and a push for innovation.
Alkem Labs to increase investment to ₹1,036 crore for new unit in Ujjain.
Yes - Free Cash Flow 5Y: ₹6390.7 Cr
Alkem's future hinges on its ability to successfully integrate Occlutech and capitalize on new product launches. Expect volatility as the market assesses the long-term impact of these strategic initiatives.
Primary Thesis Risk
Occlutech acquisition fails to deliver expected synergies and growth.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Alkem Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Alkem Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ALKEM across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (18.88%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.23%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (18.28%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 27.79 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Conservative Debt Levels (D/E: 0.15)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (19.94x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹6751.23 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 33.06%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Alkem Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Alkem Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Alkem Laboratories LtdAlkem Laborator...Selected✓ ALKEM • 539523 | 54/100 | ₹5659.00₹5659 | ₹67699.90₹67699.90 | 27.79Average 27.8 Average | 18.88%Good 18.88% Good | 21.23%Excellent 21.23% Excellent | 0.15Excellent 0.1 Excellent | 9.39%Good 9.39% Good | 10.66%Good 10.66% Good | 0.80% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹7273.00₹7273 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1438.00₹1438 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2493.00₹2493 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2543.10₹2543 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1229.50₹1230 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1550.20₹1550 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1554.30₹1554 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Biocon LtdBiocon Ltd... BIOCON • 532523 | 30.2/100 | ₹434.60₹435 | ₹70826.50₹70826.50 | 181.85Average 181.8 Average | 1.40%Poor 1.40% Poor | 3.75%Poor 3.75% Poor | 0.45Excellent 0.5 Excellent | -11.84%Poor -11.84% Poor | 18.83%Excellent 18.83% Excellent | 0.12% |
Glenmark Pharmaceuticals LtdGlenmark Pharma... GLENMARK • 532296 | 70.7/100 | ₹2297.40₹2297 | ₹64821.57₹64821.57 | 21.96Average 22.0 Average | 30.49%Excellent 30.49% Excellent | 39.77%Excellent 39.77% Excellent | 0.06Excellent 0.1 Excellent | 25.68%Excellent 25.68% Excellent | 9.19%Good 9.19% Good | 0.11% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Divis Laboratories Ltd share price193163.97 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
- Lupin Ltd share price113976.53 Cr
- Mankind Pharma Ltd share price105053.91 Cr
Alkem Laboratories Ltd PE Ratio History
Historical price-to-earnings ratio for ALKEM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹181.11 | ₹5506.50 | 30.4x |
| FY 2024 | ₹150.19 | ₹5633.90 | 37.5x |
| FY 2023 | ₹82.31 | ₹5202.60 | 63.2x |
| FY 2022 | ₹137.63 | ₹3004.70 | 21.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Alkem Laboratories Ltd Dividend History
Annual cash dividends paid by ALKEM — dividend yield 0.80%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹504.62 Cr |
| FY 2024 | ₹540.49 Cr |
| FY 2023 | ₹529.52 Cr |
| FY 2022 | ₹421.91 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Alkem Laboratories Ltd Quarterly Performance
Latest quarterly metrics for ALKEM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
14.62%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
2.04%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.66%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
9.39%
Compounded annual net profit growth over 5 years
Alkem Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ALKEM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Alkem Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Alkem Laboratories Ltd (ALKEM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Alkem Laboratories Ltd
About ALKEM (Alkem Laboratories Ltd)
Alkem Laboratories Ltd is a global pharmaceutical powerhouse, emerging from India as a dynamic force in the healthcare landscape. With a foundation built on rigorous research and d...evelopment, Alkem meticulously crafts and distributes a diverse portfolio of pharmaceutical solutions. Their commitment extends from the creation of complex formulations to the manufacture of essential medicines, all adhering to the highest international quality standards. Alkem's dedication to innovation drives them to constantly explore novel therapeutic avenues, solidifying their position as a trusted partner for healthcare providers and patients across the globe. The company has a clear vision to address unmet medical needs with an emphasis on providing accessible, affordable, and effective treatments that improve lives. The company’s reach extends across multiple continents, fostering a robust network of manufacturing facilities, research centers, and distribution channels. Alkem distinguishes itself through a vertically integrated business model, enabling greater control over the entire product lifecycle, from raw material sourcing to finished dosage forms. This approach ensures consistent quality and cost-effectiveness, giving the company a competitive edge in the global pharmaceutical market. Furthermore, Alkem’s unwavering commitment to regulatory compliance and ethical practices has earned them the respect of healthcare authorities worldwide. Their ability to navigate complex regulatory landscapes facilitates the swift introduction of innovative products into new markets, making them a preferred partner for healthcare organizations. Beyond pharmaceuticals, Alkem actively explores related healthcare domains. They are expanding their portfolio to encompass a broader range of products, focusing on preventative healthcare and overall well-being. This strategic diversification reflects Alkem's commitment to becoming a holistic healthcare provider, addressing evolving patient needs. Alkem's focus also incorporates environmental responsibility, implementing sustainable manufacturing processes and striving to minimize its environmental footprint. The company’s dedication to sustainability demonstrates its long-term commitment to responsible business practices and a healthier future for all. This forward-thinking approach positions Alkem for continued growth and success in the rapidly evolving healthcare industry.
Company Details
Key Leadership
Corporate Events
Latest News
ALKEM Share Price: Frequently Asked Questions
What is the current share price of Alkem Laboratories Ltd?
Alkem Laboratories Ltd (ALKEM) trades at ₹5659.00 on NSE and BSE. Market cap ₹67.70K (Cr). Educational data only.
What is the P/E ratio of Alkem Laboratories Ltd?
Alkem Laboratories Ltd has a P/E of 27.79x vs industry average 34.89x.
What is the Bull Run score for Alkem Laboratories Ltd?
Alkem Laboratories Ltd has a Bull Run score of 54/100 based on 25+ financial parameters.
Does Alkem Laboratories Ltd pay dividends?
Alkem Laboratories Ltd has a dividend yield of 0.80%. Past dividends don't guarantee future payments.
What is the ROE of Alkem Laboratories Ltd?
Alkem Laboratories Ltd has ROE of 18.88%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Alkem Laboratories Ltd?
Alkem Laboratories Ltd has debt-to-equity of 0.15.
Is Alkem Laboratories Ltd a good investment?
Bull Run gives Alkem Laboratories Ltd a score of 54/100. This is not investment advice — consult a SEBI-registered advisor.